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and heteroreceptor stimulation. Neurons were infected with release reporters SypHx2 or
iGluSnFR at 7 or 3 days-in-vitro (DIV) respectively. At 13–15 DIV single synaptic boutons were
identiﬁed from images obtained from a confocal scanning microscope before and after ﬁeld
electrical stimulation. We further stimulated release by raising intracellular levels of cAMP
with forskolin (10 mM). Forskolin-mediated effects were dependent on protein kinase A (PKA)
and did not result from an increase in endocytosis, but rather from an increase in the size of
the vesicle readily releasable pool. Once iGluSnFR was conﬁrmed as more sensitive than
SypHx2, it was used to study the participation of presynaptic auto- and heteroreceptors on
GLU release. Although most receptor agonizts (carbamylcholine, nicotine, dopamine D2,
BDNF) did not affect electrically stimulated GLU release, a signiﬁcant increase was observed in
the presence of metabotropic D1/D5 heteroreceptor agonist (SKF38393 10 mM) that was
reversed by PKA inhibitors. Interestingly, stimulation of group II metabotropic mGLU2/3
autoreceptors (LY379268 50 nM) induced a decrease in GLU release that was reversed by the
speciﬁc mGLU2/3 receptor antagonist (LY341495 1 mM) and also by PKA inhibitors (KT5720
200 nM and PKI14-22 400 nM). These changes in release probability at individual release sites
suggest another level of control of the distribution of transmitter substances in cortical tissue.
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Activation of presynaptic auto- and heteroreceptors contribute
to neurotransmitter release by sensing the local presence of
neurotransmitter to either inhibit or promote further release.
Cortical output neurons are presynaptically modulated by GLUautoreceptors and heteroreceptors to a plethora of neurotrans-
mitters. Although the presence of presynaptic receptors is
required, a direct presynaptic input is not. Volume transmis-
sion and spillover allow neurotransmitters to reach receptors
away from their immediate release sites. GLU is the agonist of
two classes of receptors, ion channel linked (ionotropic)
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and metabotropic receptors (mGluRs) which couple via G-
proteins to intracellular second messenger signaling path-
ways. Presynaptic modulation of GLU release by activation of
ionotropic or metabotropic (mGLUR) receptors has been well
documented (Garcia-Munoz et al., 1991a, 1991b; Lovinger et al.,
1993; Maura et al., 1988; Nicholls, 1998; O'Donnell and Grace,
1994; West and Grace, 2002) to quote just a few. Depending on
the nucleotide sequence of genes mGLURs are classiﬁed into
3 groups: mGLURs 1 and 5 (group I), mGLURs 2 and 3 (group II)
and mGLURs 4, 6, 7 and 8 (group III). Groups II and III are
usually found in presynaptic terminals as autoreceptors
(Williams and Dexter, 2014). Since mGLURs have approxi-
mately 10-fold higher afﬁnity for GLU than ionotropic recep-
tors (Gerber, 2003) their location as sensors of presynaptic
release has been considered ideal (Miller, 1998).
Evidence of modulation of GLU release by activation of
heteroreceptors in cortical terminals has also been given for
GABA (Logie et al., 2013; Waldmeier et al., 2008), acetylcholine
(Giocomo and Hasselmo, 2007; Pancani et al., 2014), dopamine
(Bamford et al., 2004; Cepeda et al., 2001), noradrenaline (Luo
et al., 2014a, 2014b), adenosine (Bannon et al., 2014; Quiroz
et al., 2009); somatostatin (Grilli et al., 2004); cholecystokinin
(Deng et al., 2006); endocannabinoids (Ferreira et al., 2012;
Lemtiri-Chlieh and Levine, 2010; Perez-Rosello et al., 2013)
and serotonin (Aghajanian and Marek, 1999; Calcagno et al.,
2006, 2009; Wang et al., 2006).
Apart from the effects of neurotensin receptor activation
that appear to be indirectly mediated by the induced release
of another neurotransmitter (Ferraro et al., 2008; Matsuyama
et al., 2003; Yin et al., 2008), direct modulation of cortical GLU
release resulting from auto- and heteroreceptor stimulation
typically occurs by stimulation of secondary intraterminal
cascades the simplest of which is the facilitation of calcium
entrance, by ionotropic GLU receptor induced depolarization,
that favors vesicle release (Perkinton and Sihra, 1999). Stimu-
lation of G-protein coupled metabotropic auto- and hetero-
receptors leads to activation of intracellular signal
transduction pathways targeting a variety of intracellular
proteins including protein kinases. A second messenger such
as calcium or cAMP typically regulates the activity of protein
kinases. Protein kinase A (PKA) and protein kinase C (PKC) are
associated with modulation of neurotransmitter release.
Studies of presynaptic events, such as those reported
above, have used a variety of methods to detect endogenous
release; stimulated release of preloaded neurons or synapto-
somes, microdialysis, postsynaptic intracellular recordings of
spontaneous and miniature depolarizing potentials or post-
synaptic currents following pair-pulse stimulation. Those
methods provide valuable data but in general their disadvan-
tage is the large population of synapses involved. Although
our basic knowledge about transmitter release is largely
based on the much simpler and more robust neuromuscular
junction, central synapses seem to have different properties
the most striking of which is the intermittent nature of
release from individual boutons. Methods recently available
that use optical reporters of exocytosis allow the precise
study of release at single boutons. In view of the variety of
modulatory inﬂuences on cortical GLU release we decided to
use two optical release reporters, synaptophysin-pHlourinx2(SypHx2) and intensity-based GLU-sensing ﬂuorescent repor-
ter (iGluSnFR). SypHx2 is the fusion of synaptic vesicle
protein synaptophysin with two molecules of the super
ecliptic pHluorin, pH-sensitive green ﬂuorescent protein
(GFP) (Burrone et al., 2006; Zhu et al., 2009), iGluSnFR is a
sensor for synaptically released GLU constructed using a
bacterial periplasmic binding protein and circularly permu-
tated GFP (Marvin et al., 2013). We ﬁrst studied release and
compared the sensitivity of the two reporters using cortical
neurons grown in vitro and stimulated the production of
cAMP with forskolin. Since cortical neuron synapses are
smaller than those typically used in release studies (i.e.,
hippocampal or cerebellar) the sensitive iGluSnFR reporter
proved superior to SypHx2 for the study of the effect of
presynaptic receptors stimulation on facilitated release.
iGluSnFR had a higher signal-to-noise ratio and detected
release after only a single pulse of electrical ﬁeld stimulation.
The effect of speciﬁc presynaptic receptor stimulation before
and after drug administration allowed us to detect changes in
release at the level of single boutons. Here we report a major
enhancing effect on GLU release at individual boutons
induced by dopamine D1/D5 receptor stimulation and an
inhibitory effect induced by a group II mGLU2/3 agonist. Both
speciﬁc hetero- and autoreceptor-mediated effects were
reversed by PKA antagonists. In summary, our results con-
ﬁrm presynaptic auto- and heteroreceptor modulation of
single pulse-induced GLU release in individual synaptic
boutons en passage of cortical neurons grown in vitro depen-
dent on the AC/PKA pathway.2. Results
The study of neurotransmitter release was signiﬁcantly
advanced by the use of synaptopHluorin (SypHx2), a ﬂuor-
escent protein designed to detect vesicle fusion at the
synapse. To detect the pH change that occurs along neuro-
transmitter release a particularly pH-sensitive variant of
green ﬂuorescent protein, ecliptic pHluorin, was fused to
the vesicular protein synaptobrevin. Once transfected and
expressed, pHluorin is quenched in the acidic lumen of
vesicles (pH5.5) and increases ﬂuorescence about 20-fold
after fusion with the plasma membrane. This reporter has
been invaluable for the study of changes in neurotransmitter
release (Balaji and Ryan, 2007; Gandhi and Stevens, 2003; Zhu
et al., 2009). As is typical for this reporter, SypHx2 signal is
optimal above 5 action potentials at 20 Hz (Gandhi and
Stevens, 2003; Zhu et al., 2009). The iGluSnFR sensor for
synaptically released GLU is produced under the synapsin
promoter and uses the periplasmic binding-protein-
dependent transport system for GLU and aspartate to anchor
the protein to the extracellular plasma membrane. The
binding of GLU to this periplasmic protein induces a con-
formational change in an inserted circularly permuted green
ﬂuorescent protein. The advantage of this reporter is that
ﬂuorescence can be detected in response of a single stimulus
(Marvin et al., 2013). In our cultures, two weeks after trans-
duction cortical neurons expressed either the SypHx2 or
iGluSnFR sensor. To report release neurons expressing
SypHx2 required ﬁve action potentials at 20 Hz (20 mA/1ms,
Fig. 1 – Comparison between release reporters SypHx2 (black) and iGluSnFR (red). Graph displays reporter induced-
ﬂuorescence to neuronal ﬁeld stimulation with different number of pulses. A small number of pulses (20 mA/1ms) induced a
larger ﬂuorescent response in the iGluSnFR (red line) than SypHx2. On the right, the regions of interest and the respective
ﬂuorescent traces (average of 5 for SypHx2 and 4 for iGluSnFR) are shown. The difference in stimulation parameters makes
the return to baseline faster for responses observed with iGluSnFR compared SypHx2 sensor.
Fig. 2 – Location of iGluSnFR or SypHx2 close to release sites was conﬁrmed by immunostaining to postsynaptic receptor
marker PSD-95 (postsynaptic density protein 95) or presynaptic receptor marker vGlut-1 (vesicular glutamate transporter 1).
A- iGlUSnFR was expressed on the extracellular surface of the postsynaptic membrane. The postsynaptic marker PSD-95
overlapped with iGluSnFR in some pucta as clearly seen in image with red frame. B- SynHx2 expression on presynaptic
boutons was conﬁrmed by its overlap with vGlut-1 as seen in the image with the red frame. iGluSnFR did not appear in
presynaptic VGlut1 marked boutons and SypHx2 was adjacent to PSD95 pucta.
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Fig. 3 – Statistical summary of results obtained following pharmacological manipulations of cAMP-dependent PKA pathway
on activity of synaptic boutons. Histograms represent percent change of silent to active boutons observed using SypHx2 (left)
or iGluSnFR (right). Statistics: ANOVA and Newman-Keuls test: ***po0.01; **po0.03; *po0.05.
b r a i n r e s e a r c h 1 6 3 9 ( 2 0 1 6 ) 7 4 – 8 7 77repeated 10 times every 5 s) whereas in neurons expressing
iGluSnFR a single electrical pulse (20 mA/1ms, repeated
4 times every 10 s) was sufﬁcient to produce a ﬂuorescent
signal large enough to be detected above noise. However, the
iGluSnFR signal saturated with 5 pulses (Fig. 1).
As expected according to the expression sites for each
reporter, immunohistochemical analyses with antibodies to
postsynaptic density protein 95 (PSD-95) or vesicular GLU
transporter 1 (vGlut-1) showed that SypHx2 was located
presynaptically whereas iGluSnFR was expressed in postsy-
naptic membranes dendrites and spines probably at synaptic
and extrasynaptic sites (Fig. 2). However, the presence of
neither reporter alone was sufﬁcient to identify synapses,
and so we identiﬁed release sites at the end of the experi-
ment in every case by following release from high frequency
stimulation. Release sites identiﬁed in this manner often do
not release in the milder conditions of our experiments. They
therefore are likely to have low probability of release in the
resting state of our cultures. Such a state is common in
central synapses generally. This interpretation is supported
by the increase in the number of release sites detected when
the extracellular calcium concentration was doubled to 5 mM.
In 2.5 mM Caþþ 9.9473.9% (n¼277 boutons; 5 different cul-
tures) and in 5 mM Caþþ 26.2773.7% (n¼251 boutons; 3 dif-
ferent cultures).
Our primary pharmacological tool to stimulate release was
forskolin since it is known to increase the probability of
release by activation of adenylate cyclase and protein kinase
A (Ariel et al., 2012; Chavez-Noriega and Stevens, 1992; Chen
and Regehr, 1997; Crawford and Mennerick, 2012; Kaneko and
Takahashi, 2004; Trudeau et al., 1996). Many of the synapses
were not releasing before the drug application but could be
recognized after the event when a ﬁnal train of high intensity
and high frequency pulses elicited release from many synap-
tic areas (release was measured as a difference in the average
ﬂuorescence change, induced by standard stimulation, before
and after drugs in a 1 mm circular region of interest centeredon the release site,-see methods section 4.6.1). The effect of
forskolin (10 mM) as studied with SypHx2 (n¼204 boutons;
6 different cultures, 31.3375.6% increase of which 1.270.6%
was from 129 previously active synapses) and with iGluSnFR
(n¼323 boutons; 4 different cultures; 42.175.6%, po0.03
increase of which 4.270.8% was contributed by 75 previously
active synapses) was mediated by cAMP-dependent PKA
pathway since, in the presence of PKA inhibitor KT5720,
release was not potentiated beyond control levels (7.970.4%
for SypHx2 n¼88; 15.470.4% for iGluSnFR n¼341 boutons;
4 different cultures each). KT5720 by itself did not signiﬁ-
cantly modify release (7.973.5% 161 synapses in 5 dishes
p40.6). In order to separate possible different intracellular
mechanisms between PKA and exchange protein activated by
cAMP (epac) we used a selective agonist of epac, 8-CPT-2’-O-
me-cAMP (100 mM) and the activator of both PKA and epac, 8-
Br-cAMP (Christensen et al., 2003). The effect of the selective
epac agonist, 8-CPT-2’-O-me-cAMP was not statistically dif-
ferent from controls excluding therefore the participation of
epac in the release we measured. As expected, the cAMP
analog 8-Br-cAMP (100 μM) resulted in an increase in release
(215 boutons, 5 different cultures, 34.677.0%, po0.01, ANOVA
and Newman-Keuls test). Fig. 3 illustrates the changes
induced by forskolin using both release reporters on respon-
sive and unresponsive synapses.
To explain the causes of activation of synapses in the
presence of forskolin we ﬁrst determined if it modiﬁed
endocytosis. As indicated in the methods (section 4.6.3) we
measured endocytosis by measuring the decay of the
reported ﬂuorescence following high frequency stimulation
since the falling phase of ΔSypHx2 signals after stimulation
reﬂects the speed of the endocytosis of synaptic vesicles
(Atluri and Ryan, 2006; Granseth et al., 2006). The time
constant of falling phase of ΔSypHx2 signal before (no drug)
14.670.88 s n¼62 and after forskolin 14.8670.85 s n¼88
did not differ (p40.86, paired t-test). To establish if the
mechanisms underlying calcium-dependent release were
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single-wavelength genetically encoded calcium indicator
GCaMP3 and observed that, consistent with ﬁndings obtained
in cerebellar and hippocampal neurons (Crawford and
Mennerick, 2012), the ratio of change in ΔGCaMP3 signal
amplitude before and after forskolin was not signiﬁcantly
different (0.2270.03 versus 0.2570.03, p40.22, n¼149 bou-
tons, paired t-test). Since the effects of forskolin were not
explained by a change intracellular calcium or endocytocis
we studied modiﬁcations on the readily releasable pool (RRP)
(Ariel and Ryan, 2010) and observed a signiﬁcant increase
after forskolin in 48 boutons becoming active (3 different
cultures) but not in the 123 already active ones (3 different
cultures) (Fig. 4). Results that are congruent with observed
activity-related changes in vesicle recruitment (Brown and
Sihra, 2008). In spite of not detecting changes in the average
RRP; initially-responsive boutons did respond to forskolin by
increasing their release (1.270.6% for SynpHx2 and 4.270.8%
in experiments with iGuSnFR)
Once we corroborated that forskolin activated individual
synapses in our cortical neurons we examined the mechan-
ism by which activation of the AC/PKA pathway led to
activation of silent cortical synapses. We had inhibited
ionotropic glutamate actions with DNQX and so the presence
of presynaptic neurotransmitter receptors was an obvious
choice. Stimulation of acetylcholine heteroreceptors with
nicotine (1 mM, 231 boutons 2 different cultures) did not
modify electrically stimulated release. Administration of
dopamine D2 heteroreceptor agonist (7)-quinpirole (0.5 mM,
197 boutons 3 different cultures) did not modify stimulated
GLU release, but the D1/D5 heteroreceptor agonist SKF38393
(10 mM) induced a signiﬁcant increase in release (24.2874.5%
16% n¼402 synaptic boutons, 4 different cultures). Similar to
the effect of forskolin, previously unresponsive boutons (91)
began to release following SKF38393 and 157 previously active
boutons increased their release by 6.570.4%. After adminis-
tration of SKF38393 a clear increase in number of responsive
synapses was also seen in neurons expressing iGluSnFR
reporter (Fig. 5 A). Neither reporter detected any changes in
unstimulated ﬂuorescence, perhaps because of the postsy-
naptic blockade of spontaneous activity with DNQX. The
signiﬁcant conversion of inactive to active synapses that
was observed after the D1/D5 agonist was reversed by protein
kinase A inhibitors KT5720 (n¼291, 3 different cultures) and
PKI14-22 (n¼318, 3 different cultures) (Fig. 5B).Fig. 4 – Measurement of the readily releasable pool (RRP) reveal
activated previously silent boutons (left) but not in the already a
ΔSypHx2/SypH signal before (black) and after forskolin (green) fSince presynaptic mGluR2/3 activation reduces neuro-
transmitter release at CNS synapses (Robbe et al., 2002) and
silencing of synapses is observed after sustained stimulation
of presynaptic adenosine A1 and GABAB receptors in hippo-
campal culture neurons (Crawford and Mennerick, 2012) our
next question was whether the activation of group 2/3 mGLU
autoreceptors in cortical neurons could change the numbers
of synapses activated. As illustrated in Fig. 6A, administration
of selective group 2/3 mGluR agonist, LY379268 (50 nM)
eliminated all ﬂuorescent signals in response to stimulation,
from iGluSnFR transfected neurons.
Overlapped average ﬂuorescent signals before and after
LY379268 also show this depressive effect (Fig. 6B). The
percentage decrease of previously active synapses following
drug administration was 37.7174.8% (Fig. 6C). Almost as
many previously active synapses reduced their release; 157
were reduced while 115 silenced completely. To determine if
the effect of LY379268 depended on actions of PKA, we
applied the speciﬁc inhibitors, KT5720 (200 nM) or PKI 14-22
(400 nM). In the presence of these PKA inhibitors the release
elicited in the presence of LY379268 reverted to typical
control values (Fig. 6C) (ANOVA and Newman-Keuls test
***po0.005, **po0.01, *po0.03, LY379268 n¼354, 6 different
cultures; LY379268þPKI14-22 n¼236, 4 different cultures;
LY379268þLY341495 n¼155, 3 different cultures). In contrast,
antagonism of GABAB receptors with CGP55845 (500 nM; 396
synapses 3 different cultures) or SCH50911 (10 mM; 256
synapses 2 different cultures) did not modify stimulated
release.3. Discussion
Here we report opposite effects on electrically induced GLU
release by presynaptic dopamine D1 and GLU mGLU2/3
receptor agonists (Figs. 5 and 6). A higher sensitivity of
iGluSnFR over SypHx2 was determined by using the typical
potentiation of release induced by forskolin (Ariel et al., 2012;
Chavez-Noriega and Stevens, 1992; Chen and Regehr, 1997;
Crawford and Mennerick, 2012; Kaneko and Takahashi, 2004;
Trudeau et al., 1996) (Figs. 1 and 2). As reported by others
(Chen and Regehr, 1997) forskolin-mediated increase in GLU
release was not dependent on intracellular calcium levels.
We conﬁrmed that forskolin-induced increase in release did
not result from an increase in endocytosis, but rather from aned that forskolin (10 lM) signiﬁcantly increased RRP in
ctive boutons (right). Traces indicate average7SEM of
or active (n¼123) and silent (n¼48) boutons.
Fig. 5 – Dopamine D1 receptors stimulate GLU release. A- D1 receptor agonist SKF38393 (10 lM) induced an increase in
electrically stimulated GLU release as observed in ﬂuorescent ΔiGluSnFR images and sample traces. B- Histogram of
percentage of activated silent boutons in the presence of SKF38393 (n¼402) and reversal of the effect following protein kinase
A inhibitors KT5720 (n¼291) and PKI14-22 (n¼318) (ANOVA and Newman-Keuls test *po0.03).
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activated by forskolin (Fig. 4).
Individual synaptic variability in the size of the RRP (Ariel
et al., 2012) could be related to the response of previously
inactive boutons to forskolin (Chavis et al., 1998; Tong et al.,
1996). The identity of target neurons and the local environ-
ment around the synapse most likely inﬂuence neuronal
presynaptic receptor expression and release characteristics.
An advantage of working with neurons grown in vitro is that
some of these variables are restricted. Our results indicate
that in spite of lack of long-range input and output targets,
neurons in culture express presynaptic receptors that control
their release. Although such preparations are subject to
homeostatic plasticity that has been a source of silenced
synapses we worked with the normal variation in release
probability in untreated cultures. Moreover, the observed
changes in the number of active boutons following forskolin
(Fig. 3) and presynaptic receptor activation (Figs. 5 and 6)
indicate an important contribution of presynaptic receptors
to plasticity, even though we blocked the normal postsynap-
tic activity with DNQX in the perfusion solution.
Although the reported inactive synapses were stable over
the course of our experiments it is possible that over
physiological time scales in vivo they may just be the
consequence of the stochastic release process known to be
common in boutons “en passage” in other areas of the brain.3.1. Modulation of glutamate release by presynaptic
dopamine D1 receptors
The postsynaptic inﬂuence of dopamine on cortical functions
such as attention, motivation, appetite and memory (Cools
and D'Esposito, 2011; Fan et al., 2014; Marazziti et al., 2013;
Michaelides et al., 2012; Palmiter, 2011) and several patholo-
gies such as schizophrenia, depression, drug addiction and
attention deﬁcits (Arnsten, 2009; Chen and Yang, 2002;
Duman and Voleti, 2012; Russo and Nestler, 2013) has rein-
forced the idea of a close presynaptic and postsynaptic
dopamine/GLU collaboration.
Presynaptic receptors ﬁne-tune release activity at synapses.
Reciprocal interaction between dopamine and GLU involving
presynaptic auto- and heteroreceptors takes place at conver-
gent axonal terminal ﬁelds in prefrontal cortex and sites of
cortical input to striatum and nucleus accumbens (French and
Totterdell, 2002; Johnson et al., 1994; Sesack and Pickel, 1990,
1992; Totterdell and Smith, 1989). Of the several dopaminergic
systems in the brain, the mesencephalic areas A8, A9 and A10
innervate cortical neurons and areas where these neurons
send axons (e.g. striatum, hippocampus and amygdala)
(Dahlstrom and Fuxe, 1964). Presynaptic D1 and D2 receptors
are present on cortical and basal ganglia GLU-containing
terminals (Bergson et al., 1995; Dumartin et al., 2007;
Paspalas and Goldman-Rakic, 2005). The participation of D2
Fig. 6 – Active boutons can be turned off. A- Stimulation of group II mGLU2/3 presynaptic autoreceptors with LY379268 (50 nM)
induced a decrease in electrically stimulated GLU release as observed ΔiGluSnFR images and sample traces. B- Ovelaped
average ﬂuorescent traces before (black) and after LY379268 ( blue). C- Histogram of percentage of silenced boutons in the
presence of LY379268 and reversal to active baseline levels observed following administration of protein kinase A inhibitor
KT5720 (n¼277), PKI-14-22 (n¼236) or mGLU2/3 receptor antagonist 341495 (n¼155) (ANOVA and Newman-Keuls test
***po0.005, **po0.01).
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and Invernizzi, 2014; Ferraro et al., 2012; Flores-Hernandez
et al., 1997; Garcia-Munoz et al., 1991a; Hsu et al., 1995; Maura
et al., 1988; Nicholls, 1998; O'Donnell and Grace, 1994). Facil-
itation of GLU release by speciﬁc activation of D1 receptors was
more difﬁcult to establish. Electrophysiological studies were
the ﬁrst to indicate that dopamine D1 and D2 receptor agonists
had opposite actions in postsynaptic membrane excitability
(Cepeda et al., 1992, 2001; Chu et al., 2010; Hernandez et al.,
2007; Seamans and Yang, 2004; West and Grace, 2002). Differ-
ential responses according to dopamine concentration (Zheng
et al., 1999) or striatal neuronal type (direct and indirect output
neurons) (Andre et al., 2010) have also been reported.
Studies of the direct effect of D1 receptor stimulation on
GLU release are few (Abekawa et al., 2000; Bouron and Reuter,
1999). Here using iGluSnFR we report in cortical neurons
grown in vitro that electrical stimulation with a single pulse
potentiated GLU release observed in single boutons after
speciﬁc dopamine D1/D5 receptor stimulation. Moreover, as
seen in Figs. 3–5 we conﬁrmed that the drug-induced increase
in release was sufﬁcient to activate previously unresponsive
boutons.3.2. Presynaptic group II metabotropic glutamate
autoreceptors
It has been established that one of the physiological effects of
group II mGluRs is to negatively modulate neurotransmitter
release from nerve endings that express 2/3 mGluRs as
autoreceptors (Bushell et al., 1996; Conn and Pin, 1997;
Raiteri, 2008; Romei et al., 2013) or as heteroreceptors in
terminals releasing GABA (Petralia et al., 1996; Schaffhauser
et al., 1998). Here we report a decrease in electrically stimu-
lated GLU release and an associated conversion of responsive
to inactive synapses (Fig. 6). It remains to be established if the
plastic effect of inactivating synapses lasts long enough to
possibly have an enduring therapeutic effect in pathological
states of hyperactive glutamatergic synapses such as epilepsy
or schizophrenia (Hiyoshi et al., 2014). Although long term
changes as a result of mGluR activation have been reported
and those are also inhibited by PKA the ﬁnal action of the
presynaptic receptors seems likely to be via voltage gated
calcium channels in the terminals. Indeed, in some experi-
ments these seem to be the dominant effectors, in others the
calcium channels are modiﬁed by PKA actions consequent
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on the site in brain that is investigated as well as the time
course of the effect studied we have no deﬁnitive experi-
ments to decide the molecular site of action in our cultures.
3.3. Consequence of presynaptic receptor activation on
release at individual synapses
Much research related to synaptic strength concentrates on
activity-dependent alterations produced by modiﬁcations
either in synaptic efﬁcacies or synaptic wiring e.g.,
(Chklovskii et al., 2004). Silent presynaptic synapses also
described as mute, inactive or dormant, do not release
neurotransmitter until certain activity dependent modiﬁca-
tions are achieved. They have been described for excitatory
and inhibitory neurotransmitters and have been observed in
invertebrates (e.g., snail, aplysia, drosophila) and vertebrates
(e.g., ﬁsh and mammals) (Doussau et al., 2010; Kim et al.,
2003; Massobrio et al., 2013; Peled and Isacoff, 2011). Under
particular network demands they are activated or awakened
representing what has been described as “a golden reserve for
plasticity” (Voronin et al., 2004; Voronin and Cherubini, 2004).
The synapses in our study were not active at rest and not
during the experimental stimulation in the absence of activa-
tion by drugs. We identiﬁed them by their response to
stronger stimulation at the end of the experiment suggesting
that they had a high threshold for release perhaps because of
a low probability of vesicular release. Typically, an increase in
synaptic efﬁcacy is accompanied by an increase in presynap-
tic neurotransmitter release, an increase in postsynaptic
receptor efﬁcacy or both. Here we report that in the presence
of forskolin, previously unresponsive boutons became active
(Fig. 3) with an associated increase in the size of readily
releasable pool (Fig. 4). Importantly, we report that speciﬁc
activation of dopamine D1/D5 receptors also produced an
activating effect (Fig. 5), whereas stimulation of presynaptic
group II mGlu2/3 receptors reduced the number of responsive
synapses (Fig. 6). In both cases inhibitors of PKA reversed the
“unresponsive to active” or “active to unresponsive” conse-
quences of presynaptic receptor stimulation. In contrast to
areas like hippocampal mossy ﬁber synapses or Calyx of Held
(Kaneko and Takahashi, 2004) activation of the alternative
cAMP activated Epac pathway did not have any effect on the
number of activated synapses (Fig. 3).
There is ample evidence for postsynaptic silent synapses
on cortical and hippocampal neurons dependent on the
presence and function of NMDA receptors but not AMPA
receptors. These silent synapses become active following
induction of LTP and postsynaptic insertion of functional
AMPA receptors (Kerchner and Nicoll, 2008). A pre- and post-
synaptic mechanism for silent synapses that coexists and
unfolds at different times has also been proposed (Choi et al.,
2003). Certainly, it has been argued that synapses can be
presynaptically rather than postsynaptically silent (Cousin
and Evans, 2011; Ma et al., 1999a; Moulder et al., 2008; Voronin
et al., 2004). The cAMP pathway via cAMP-dependent protein
kinase A (PKA) is implicated in the increase in synaptic
release that leads to the activation of silent synapses of
various neuronal types (Cousin and Evans, 2011; Huang and
Hsu, 2006; Ma et al., 1999b; Yao et al., 2006).3.4. Bidirectional presynaptic regulation
G-protein-mediated signaling cascades and second messen-
gers are most likely the basis for the observed presynaptic
interaction of dopamine D1 and mGLU2/3 receptors. Because
of our experimental design we have not tested the action of
mGluR activation on D1 modiﬁed synapses themselves – the
contrasting actions were recorded from different cultures. We
observed that both the enhancing and inhibitory effects on
release are modulated by PKA, since speciﬁc PKA antagonists
prevented the effects not only of forskolin (Fig. 3) but also of
speciﬁc agonists to dopamine D1 (Fig. 5) and mGLU2/3 (Fig. 6)
receptors.
The potential site of action for PKA is downstream of
calcium entry affecting the release process by recruitment/
replenishment of synaptic vesicles, increase of the size of the
readily releasable pool and exocytosis/fusion (Brown and
Sihra, 2008) (Fig. 4). Of course the sign of the action of PKA
on release is different after D1 or mGluR treatment and so we
expect different intracellular cascades to be involved in the
two cases. Although the site of action of the drugs is most
likely to be on the known receptors on the terminals them-
selves we cannot directly exclude other sites of action, such
as glial cells or axonal actions. Network actions were reduced,
in our experiments, by the blockade of postsynaptic receptors
for glutamate with DNQX.
The participation of intracellular cascades and their cross-
talk in plasticity related events has been well studied
(Atwood et al. (2014) for review). Speciﬁc examples involving
dopamine and mGLUR3 (Williams and Dexter, 2014), dopa-
mine D1 and mGLU5R (Fieblinger et al., 2014) and the
bidirectional responses to dopamine D1 and mGLU2/3 recep-
tors observed in the rat basolateral amygdala (Li and Rainnie,
2014) underline the importance of presynaptic receptor-
mediated modulation of neurotransmitter release in plasti-
city, neuroprotection and brain dysfunction.
Convergence of axon terminals in close proximity pro-
vides an ideal arrangement for presynaptic interaction and
an important form of control of neurotransmitter release.
High afﬁnity presynaptic receptors can be considered as
detectors and regulators of neurotransmitter release to main-
tain a homeostatic balance when ﬂuctuations in release
change physiological states.4. Experimental procedures
We used cultured neurons expressing ﬂuorescent reporters of
vesicle release: SypHx2 or iGluSnFR. A synaptic bouton was
identiﬁed from confocal scanning microscope images
obtained before and after ﬁeld electrical neuronal stimulation
via two platinum wires on either side of the cultures. Drugs
were added to the circulating medium 20 min before running
an automated data acquisition cycle controlled by the micro-
scope’s computer. Off-line data analysis was performed after
a ﬁnal strong stimulation (40 pulses, 20 Hz) was delivered to
identify all release sites. A region of interest (ROI, 1 mm
diameter) was set around release sites so identiﬁed and they
were then separated into responsive and inactive boutons, as
seen in the previous states of the experiment.
b r a i n r e s e a r c h 1 6 3 9 ( 2 0 1 6 ) 7 4 – 8 7824.1. Optical imaging
Coverslips containing cultured neurons (13–15 DIV) were
mounted on a laminar ﬂow chamber (Warner Instruments
LLC, CT USA) and perfused with artiﬁcial cerebrospinal ﬂuid
(ACSF) containing 124 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3,
1 mM NaH2PO4, 2.5 mM CaCl2, 2.5 mM MgCl2 maintaned at pH
7.4 with 95% O2 and 5% CO2 gas. AMPA/kainate receptors
were blocked with DNQX (10 mM) added to the medium.
Medium was circulated at a rate of 2 ml/min (Perista Atto,
Tokyo Japan) and maintained at 28 1C with a temperature
controller (Warner Instruments, CT, USA).
Neurons were imaged (256256 pixels at 16 Hz) using a
confocal scanning microscope (Olympus). Fluorescence of
release sensors (SypHx2 and iGluSnFR) or calcium indicator
(G-CaMP3) was excited with an argon laser at 488 nm ﬁltered
at 510–610 nm through a 60x objective of NA 1.1 and 2.0 mm
working distance. The membrane-selective marker of endo-
cytosis dye FM4-64 (Molecular probes, OR, USA) was excited
with argon laser at 543 nm and collected through a 580–
680 nm ﬁlter. Throughout the experiments laser power was
ﬁxed and ﬂuorescence intensity expressed as arbitrary ﬂuor-
escent units (AFU) measured at ﬁxed sensitivity.
A microscope computer ran data acquisition cycles that
started with neuronal ﬁeld stimulation triggered after a 10 s
delay. Electrical ﬁeld stimulation (delivered through two pla-
tinum wires attached to the culture dish) with parameters
optimized according to the release reporter:- to 1 ms/ 20mA
delivered at 20 Hz for 250 ms (5 pulses) repeated every 5 s for
SypHx2 and a single 1ms/ 20mA pulse repeated four times
every 10 s for iGluSnFR. When needed, stimulation cycles were
repeated allowing 5 min of recovery between runs. In different
experiments the following drugs were administered in ACSF
(pH 7.4) in the presence of AMPA/kainate receptor antagonist
DNQX (Tocris, 10 mM). Drugs obtained from Sigma: cAMP
activator forskolin (10 μM), speciﬁc cell-permeable inhibitor of
protein kinase A (PKA) KT5720 (200 nM), cell permeable cAMP
analog 8-bromoadenosine 3’, 5’-cyclic monophosphate (8-Br-
cAMP 100 μM), cholinergic agonist nicotine (1 mM). Drugs
obtained from Tocris: analog cAMP-activated guanine
exchange factor Epac, 8-(4-chlorophenylthio)2’-O-methyl
adenosine 3’,5’-cyclic monophosphate monosodium hydrate
(8-pCPT-2’-O- Me-cAMP, 100 μM), dopamine D2 receptor ago-
nist (7)-quinpirole (500 nM), protein kinase A inhibitor myr-
istolyated PKI 14-22 amide (400 nM), group II mGlu receptor
agonist LY379268 (50 nM), group II metabotropic GLU receptor
antagonist LY341495 (1 mM) and D1 dopamine receptor agonist
SKF 38393 hydrobromide (10 mM). To avoid drug interaction
with our synapse identiﬁcation, a 30min washout following
drug administration was performed before identifying respon-
sive release sites to high frequency stimulation.
4.2. Cell cultures
Mice handling, killing and embryonic tissue dissection were
performed under protocols approved by the University and in
compliance with Japanese guidelines (Law for Humane Treat-
ment and Management of Animals, the Fundamental Guide-
lines for Proper Conduct of Animal Experiments and Related
Activities in Academic Research Institutions and theGuidelines for Proper Conduct of Animal Experiments). More-
over, the experimental procedures abided by the ethical
standards set by the Society for Neuroscience as described
on the Responsible Conduct Regarding Scientiﬁc Communi-
cations. We obtained brain cells from C57BL/6 J mice embryos
of 14-16 days post fertilization. Cortical tissue removed from
embryos was dissected under a microscope in ice-cold Hanks
balanced salt solution (HBSS, Invitrogen) containing 15 mM
HEPES. Tissue was cut into smaller pieces and incubated in
0.4% DNase-1 (Sigma-Aldrich)/0.25% trypsin (Invitrogen) for
30 min in the 37 1C followed by suspension, centrifugation
and re-suspension.
Cells were counted under a microscope using a hemocyt-
ometer (Bright-Line, Housser Scientiﬁc, Horsham, PA). We
plated neurons in NbActiv4 medium (BrainBits, LLC, UK) on
25 mm diameter coverslips pre- coated with 10 μg/ ml poly-L-
lysine (Sigma-Aldrich) at a density of 3105 cells. For the ﬁrst
24 h in culture only, the NbActiv4 medium was supplemented
with 5% heat-inactivated horse serum and 1% penicillin/
streptomycin. We maintained cultures in a CO2 humidi-
ﬁed incubator at 37 1C in NbActiv4 with 1% penicillin/strep-
tomycin. Half of the culture medium was exchanged twice a
week with new medium containing 1% penicillin/streptomy-
cin. No measures were taken to exclude, or encourage glial
cells which are present in our cultures.4.3. Viral production
Lentiviruses were produced by triple transfection of HEK
293 T/17 cells (ATCC, VA, USA) with pLentivirus, pMD2.G
and psPAX using FuGENE6 transfection reagent (Roche, Basel
Switzerland) as described by (Boyden et al., 2005) with the
following modiﬁcations: A total of 106 HEK 293 T/17 cells were
seeded in 4 plates (10 cm diameter) 24 h prior transfection in
Dulbecco’s modiﬁed eagle medium (DMEM) (Invitrogen) sup-
plemented with 5% fetal bovine serum, 0.075% sodium
bicarbonate, 1% glutamax (Invitrogen), 1% penicillin (1 IU/
ml)/streptomycin (1 μg/ml) and 1 mM sodium pyruvate. All
chemicals were obtained from Sigma, unless otherwise
noted. We used a total of 7.3 mg of pLenti-syn-SypHx2 plas-
mid, 2.3 mg of pMD.2.G and 5 mg of psPAX for the transfection
of each 10 cm dish. The precipitate was formed by adding the
plasmids to 640 ml of serum-free DMEM (without supple-
ments) for 5 min followed by 44 μl of FuGENE6 brieﬂy mixing
with a vortexer. Incubation was carried out for 15 min at
room temperature and the DNA/liposomal mixture was
added to culture dishes. Cultures were maintained in a CO2
humidiﬁed incubator (Sanyo, Osaka Japan) at 37 1C. After an
incubation period of 5–6 h, medium was replaced with
ultraculture medium (Lonza, Basel Switzerland) supplemen-
ted with: 0.075% sodium bicarbonate, 1% glutamax, 1%
penicillin (1 IU/ml)/ streptomycin (1 μg/ml), 0.5 μM sodium
butyrate and 1 mM sodium pyruvate. We collected the con-
ditioned medium containing extruded viruses after 48 h,
concentrated it by ultracentrifugation and determined the
viral titer using Lenti-X qRT-PCR Titration Kit (Takara, Osaka
Japan).
b r a i n r e s e a r c h 1 6 3 9 ( 2 0 1 6 ) 7 4 – 8 7 834.4. Viral infection
Cortical cultures were infected at 7 days-in-vitro (7 DIV) using
200x serial dilution of lentivirus including SypHx2 RNA
(5107 IFU/ml), adeno-associated virus stereotype 2/1
(AAV2/1) including G-CaMP3 DNAs (1.0109 IFU/ml) or with
AAV2/9 including iGluSnFR DNAs (1.2109 IFU/ml, Univer-
sity of Pennsylvania Vector Core) at 3 DIV. Viral dilutions
were added to cortical cultures seeded on 25 mm coverslips
and incubated at 37 1C for a day, after incubation culture
medium was exchanged with fresh medium.
4.5. Immunohistochemistry
Cultures were ﬁxed in 4% paraformaldehyde for 60 min at
room temperature, rinsed three times with 10 mM phosphate
buffered saline (PBS) and stored at 4 1C. Cultures were
permeabilized and blocked in cold PBS with 0.3% tritonX-
100 and 20% normal goat serum for 60 min at room tempera-
ture. After washing with PBS, cultures were incubated with
primary antibodies diluted in 10 mM PBS containing 0.3%
triton-X100 overnight at 4 1C. The primary antibodies were
mouse anti-PSD-95 (Gilbert, #30398) and guinea pig anti-
vesicular GLU transporter 1 (vGlut-1) (Abcam, Tokyo, Japan).
After overnight incubation cultures were rinsed with 10 mM
PBS. Alexa ﬂuor 594 conjugated secondary antibodies (1:500)
(Invitrogen) were incubated for 3 h at room temperature and
rinsed again. Fluorescence images were obtained under con-
focal microscope (Olympus, Fluoview FV1000 MPE, Tokyo,
Japan).
4.6. Measurements and data analysis
4.6.1. Identiﬁcation of synapses
We identiﬁed synapses by working in reverse through the
series of images captured by the computer, using the last of
the series (at 20 Hz, 40 pulses) to identify release sites and
quiet sites activated over the course of treatments before the
ﬁnal stimulation, thereby identifying the processes that lead
to sites becoming active. The off-line data analysis (Image J
http://rsb.info.nih.gov/ij/) started from the last experimental
condition, i.e., “identiﬁcation of active synaptic boutons”.
Stacks of images were obtained during ﬁeld stimulation ﬁve
for SypHx2 and ten for iGluSnFR. Frames before and after
stimulation were averaged separately and subtracted from
each other to produce a differential ﬂuorescence or ΔF image.
The ΔF image was then median-ﬁltered at 3 pixels. If boutons
were not clearly observed at this point the analysis was not
performed. Bright ﬂuorescent spots in the same focal plane
were used as landmarks for synaptic boutons identiﬁed
during the ﬁnal stimulation procedure to ﬁnd release sites.
The mean noise amplitude was calculated as the standard
deviation of points before electrical stimulation. Ten
responses to stimulation were averaged and the signal range
was calculated by subtracting the average of 20 points before
electrical stimulation from 10 points after electrical stimula-
tion. If this value was greater than the standard deviation of
the signals before stimulation (signal to noise value; S/N41),
it was deﬁned as an active synapse in experiments with
SypHx2 (for iGluSnFR; S/N41.0 and for G-Camp3; S/N42). Theregion of interest (1 mm diameter) was set around responsive
and silent boutons and the analysis of responses to stimula-
tion in the presence of drugs started. The change in ﬂuores-
cence from both previously inactive and previously active
synapses were averaged to measure the effect of the
applied drugs.
To verify the pH-sensitive response of the synaptic bou-
tons expressing SypHx2, images were obtained while applying
a solution of ammonium chloride (NH4Cl 50 mM) pH of
7.4 prepared by replacing NaCl (50 mM) in the standard ACSF.
The lack of saturation of SypHx2 results was demonstrated by
comparison with the saturated images obtained after NH4Cl
perfusion. for 2 min
4.6.2. Determination of calcium dependency
To identify whether changes in calcium inﬂux were related to
the process of activating individual boutons, cortical neurons
were infected with AAV expressing the calmodulin-
associated ﬂuorescence indicator GCaMP3. Images obtained
with this indicator were sampled before and after forskolin
administration, and then the membrane-selective marker of
endocytosis FM4-64 (1 mM) was loaded and unloaded to
clearly differentiate presynaptic sites from other areas of
the neuron expressing GCaMP3. Neurons exposed to FM4-64
were incubated in the dark for 2 min in ACSF containing the
NMDA GLU receptor antagonist D-AP5 (50 mM, Tocris, Bristol
UK). To promote internalization of the dye neurons were
exposed to KCl (100 mM) for 2 min. To remove external dye
and reduce background staining neurons were incubated for
5 min in ACSF containing 100 mM ADVASEP-7 (Biotium, CA,
USA) plus 50 mM D-AP5 followed by continued washing in the
normal ACSF for 15 min. Images were acquired after washing.
To verify the lack of saturation of G-CaMP3 signals the
internal concentration of calcium was increased by perfusion
of the calcium ionophore ionomycin (1 mM in ACSF) for 3 min
and images collected at the end of experiments.
4.6.3. Determination of endocytosis
Endocytosis was measured by strong stimulation (40 stimuli
at 20 Hz) and SypHx2 ﬂuorescence image collection. After
high frequency stimulation the decay of SypHx2 ﬂuorescence
corresponds to a sum of endocytosis and reacidiﬁcation of
the vesicular contents (Atluri and Ryan, 2006; Granseth et al.,
2006). Using Origin pro software (version 8.6 J) the averaged
ﬂuorescent response curves were normalized aspercent of
peak ﬂuorescence, followed by a 10-point average ﬁlter. The
rate of endocytosis or τe was calculated by applying the fol-
lowing formula to normalized ﬂuorescent curves: F(t)¼
A1*EXP(t/τe)þA2*EXP(t/τr)þΨ0 where A1 and A2 are posi-
tive values of averaged ﬂuorescent response amplitudes, τe
and τr are time constants for endocytosis and reacidiﬁcation
respectively. Reacidiﬁcation or τr was ﬁxed to the typical
value of 4 s. A value of Ψ0 as 0.3 provided the best ﬁt to our
data. Once τe was calculated the adjusted R-square of F(t)
greater than 0.8 conﬁrmed the best adjustment (Atluri and
Ryan, 2006; Granseth et al., 2006).
4.6.4. Determination of the readily releasable pool size (RRP)
We used the method of Ariel and Ryan (2010) to determine
the size of RRP at single synapses. This method uses
b r a i n r e s e a r c h 1 6 3 9 ( 2 0 1 6 ) 7 4 – 8 784continuous high frequency stimulation (20 pulses at 100 Hz)
to exhaust the process of exocytosis. Using a rapid line-scan
mode we determined that the ﬂuorescence plateau was
reached between 10 and 20 pulses. As explained in section
4.6.1, at the end of the experiments we appliedammonium
chloride (NH4Cl) for 2 min. The size of the readily releasable
pool was calculated from the SypHx2 ﬂuorescence intensity
within each region of interest by subtracting 5 points before
electrical ﬁeld stimulation from the ﬁnal 5 points after high
frequency stimulation. The value of the ΔSypHx2/SypHx2
reﬂected the size of the RRP. We illustrate that value (Fig. 4)
but we calculated SypHx2/NH4Cl ﬂuorescence as used by
Ariel and Ryan (2010) and obtained similar results.4.6.5. Statistics
Statistical signiﬁcance was tested by the t-test for paired data
or with one-way analysis of variance ANOVA and post hoc
multi comparison performed by the Newman-Keuls test
using IGOR Pro and R software (WaveMetrics, Inc. Oregon
USA versions 6.34 A and 2.14.1 respectively). Typically, data
was expressed as mean7SEM (number of experiments)
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